UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Frontiers in endocrinology (Lausanne), 2021-06, Vol.12, p.645617

Meier, Juris J

2021

Volltextzugriff (PDF)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Molecular metabolism (Germany), 2021-04, Vol.46, p.101102-101102, Article 101102

2021

Volltextzugriff (PDF)

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

The lancet. Diabetes & endocrinology, 2016-06, Vol.4 (6), p.525-536

2016

Volltextzugriff (PDF)

GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

Diabetes (New York, N.Y.), 2019-05, Vol.68 (5), p.897-900

2019

Volltextzugriff (PDF)

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.699-704

2020

Volltextzugriff (PDF)

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.216-227

2017

Volltextzugriff (PDF)

Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy

Frontiers in endocrinology (Lausanne), 2019-02, Vol.10, p.45

2019

Volltextzugriff (PDF)

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1385-1397

2023

Volltextzugriff (PDF)

SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?

Endocrinology (Philadelphia), 2020-08, Vol.161 (8), p.1

2020

Volltextzugriff (PDF)

The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide

Diabetes, obesity & metabolism, 2023-11, Vol.25 (11), p.3079-3092

2023

Volltextzugriff (PDF)

Incretin hormones: Their role in health and disease

Diabetes, obesity & metabolism, 2018-02, Vol.20 (S1), p.5-21

2018

Volltextzugriff (PDF)

Prospective External Validation of an Algorithm Predicting Hourly Basal Insulin Infusion Rates from Characteristics of Patients with Type 1 Diabetes Treated with Insulin Pumps

Experimental and clinical endocrinology & diabetes, 2023-10, Vol.131 (10), p.539-547

2023

Volltextzugriff (PDF)

Importance of localization of insulinomas: a systematic analysis

Journal of hepato-biliary-pancreatic sciences, 2019-09, Vol.26 (9), p.383-392

2019

Volltextzugriff (PDF)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations

Frontiers in endocrinology (Lausanne), 2021-09, Vol.12, p.760153-760153

2021

Volltextzugriff (PDF)

Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study

BMC microbiology, 2022-06, Vol.22 (1), p.1-169, Article 169

2022

Volltextzugriff (PDF)

Treatment of type 2 diabetes: challenges, hopes, and anticipated successes

The lancet. Diabetes & endocrinology, 2021-08, Vol.9 (8), p.525-544

2021

Volltextzugriff (PDF)

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Diabetes, obesity & metabolism, 2017-09, Vol.19 (9), p.1327-1328

2017

Volltextzugriff (PDF)

Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective

Diabetes and Metabolism Journal, 2023, 47(1), 195, pp.140-146

2023

Volltextzugriff (PDF)

Increased incidence of GERD in GLP-1 treated patients: fact or artefact?

Gut, 2024-09, Vol.73 (9), p.1588-1589

2024

Volltextzugriff (PDF)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

Diabetes, obesity & metabolism, 2020-08, Vol.22 (8), p.1263-1277

2020

Volltextzugriff (PDF)

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

The lancet. Diabetes & endocrinology, 2016-12, Vol.4 (12), p.963-964

2016

Volltextzugriff (PDF)

Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope

Diabetes, obesity & metabolism, 2019-05, Vol.21 (5), p.1081-1087

2019

Volltextzugriff (PDF)

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Circulation (New York, N.Y.), 2017-08, Vol.136 (9), p.849-870

2017

Volltextzugriff (PDF)

Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

Diabetes care, 2020-12, Vol.43 (12), p.2906-2909

2020

Volltextzugriff (PDF)

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Diabetes, obesity & metabolism, 2017-03, Vol.19 (3), p.336-347

2017

Volltextzugriff (PDF)

1 – 25 von 146

Suche als RSS-Feed

Aktive Filter

KollektionNature

ThemaDiabetes. Impaired Glucose Tolerance

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(133)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Life Sciences & Biomedicine
(75)
Endocrinology & Metabolism
(56)
Humans
(56)
Diabetes
(42)
Type 2 Diabetes
(33)
Diabetes Mellitus
(26)
Diabetes Mellitus, Type 2 - Drug Therapy
(23)
Insulin
(21)
Glucagon
(19)
Glucose
(17)
Hypoglycemic Agents - Therapeutic Use
(14)
Animals
(13)
Body Weight
(13)
Peptides
(12)
Antidiabetics
(11)
Biological And Medical Sciences
(11)
Glucagon-Like Peptide 1
(11)
Insulin Secretion
(11)
Clinical Trials
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?

The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide

Incretin hormones: Their role in health and disease

Prospective External Validation of an Algorithm Predicting Hourly Basal Insulin Infusion Rates from Characteristics of Patients with Type 1 Diabetes Treated with Insulin Pumps

Importance of localization of insulinomas: a systematic analysis

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations

Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study

Treatment of type 2 diabetes: challenges, hopes, and anticipated successes

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective

Increased incidence of GERD in GLP-1 treated patients: fact or artefact?

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Aktive Filter

Suchergebnisse filtern